| ADAGENE INC. SP.ADR |
| USA |
| Gesundheit |
| US0053291078 / A2QN45 |
| 978 (Frankfurt) / ADAG (NASDAQ) |
| FRA:978, ETR:978, 978:GR, NASDAQ:ADAG |
| - |
| https://www.adagene.com/ |
|
Adagene Inc. is a biotechnology company focused on the discovery and development of innovative antibody-based therapies. The company's primary function is to harness its proprietary Dynamic Precision Library (DPL) platform to generate novel therapeut..
>Volltext.. |
| 154.45 Mio. EUR |
| 106.05 Mio. EUR |
| 0.09 Mio. EUR |
| -28.26 Mio. EUR |
| -25.9 Mio. EUR |
| -0.56 EUR |
| 5.92 Mio. EUR |
| 54.32 Mio. EUR |
| -23.82 Mio. EUR |
| 2.2 |
| -87.59% |
| 6.87% |
| - |
| - |
| - |
| - |
| ADAGENE |
| 02.04.26 |
|
||||
|